TUSTIN, Calif., March 6 AMDL, Inc. (NYSE Alternext US: ADL), a US-based pharmaceutical company with major operations in China, announced today its Executive Chairman and Chief Executive Officer Mr. Douglas MacLellan will present at Security Research Associates' (SRA) 5th Annual Winter Technology Conference on Monday, March 9, 2009.
During the 5th Annual Winter Technology Conference, Mr. MacLellan will provide details of AMDL's 2009 business strategy, expanding product portfolio, and FY2009 financial projections. Mr. MacLellan's presentation will take place at 12:30 p.m. PDT in the Russian Room in the Omni Hotel located in San Francisco, CA. Conference attendees will include a select group of institutional portfolio managers and analysts and feature CEOs and CFOs from some of the fastest growing companies in the technology sector.
Founded in 1987, AMDL operates three distinct business divisions that include: (i) In Vitro Diagnostics, (ii) Cancer Therapeutics, and (iii) China-based pharmaceutical manufacturing and distribution. Collectively, these business units focus on the development, manufacturing, distribution and sales of high quality generic pharmaceuticals, nutritional supplements, cosmetic and medical diagnostic products in the US, China, Korea, Taiwan and other markets throughout the world.
For the past four consecutive fiscal years, AMDL has achieved 100% or more growth in gross revenues and expects to continue this forward momentum in 2009 as it executes an aggressive business strategy focused on expanding its market presence in China and other select international markets. Management issued financial guidance for FY2009 forecasting gross revenues between US$64 to $72 million, and net income between US$8 and $12 million after taxes and before foreign currency translation gains or losses. This guidance represents sales for AMDL's China-based operations only and does not include product sales for DR-70 or Elleuxe. AMDL believes anticipated revenues from these two products could potentially result in an additional US$25 million in additional gross revenues.
In FY2008 AMDL achieved gross revenues between $32 million - $36 million vs. $15 million in FY2007, and net income after foreign currency translation of between $2.4 and $2.6 million. For FY 2007, net loss after foreign currency translation was approximately $1.26 million.
AMDL is listed on the American Stock Exchange Alternext US under the symbol "ADL". In 2007, AMDL earned $15 million in gross revenues and the Company plans to issue 2008 earnings results later this month. AMDL employs approximately 510 people in the US and China.
Webcasting of all Company presentations during the SRA conference will be accessible following the event by visiting: http://www.wsw.com/webcast/sra8/ .
Headquartered in Tustin, CA with operations in China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The Company employs over 490 people in the US and China.
About Security Research Associates, Inc.
Security Research Associates, Inc. (SRA) was founded in San Francisco in 1980 and, today, offers investment banking and M&A services as well as institutional brokerage services. A boutique firm by design, SRA works with a select group of portfolio managers from around the country and focuses on technology and life science companies in the micro and small cap arenas. For more information about SRA see our web site at www.sracap.com or call us at 415-925-0346.
Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to AMDL, Inc., except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.
AMDL Contact: Kristine Szarkowitz Director-Investor Relations email@example.com (Tel:) 714.380.8832
SOURCE AMDL, Inc.